1. Home
  2. BBIO

BBIO

BridgeBio Pharma Inc.

Logo BridgeBio Pharma Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.

Founded: 2015 Country:
United States
United States
Employees: N/A City: PALO ALTO
Market Cap: 5.7B IPO Year: 2019
Target Price: $45.40 AVG Volume (30 days): 1.7M
Analyst Decision: Strong Buy Number of Analysts: 10
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -3.95 EPS Growth: N/A
52 Week Low/High: $12.75 - $44.32 Next Earning Date: 05-02-2024
Revenue: $9,303,000 Revenue Growth: -88.02%
Revenue Growth (this year): 1017.92% Revenue Growth (next year): 89.80%

Share on Social Networks: